Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cellular

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  Next»
    Study title:
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47163
    Study title: An open, randomised, controlled, phase III study of the immunogenicity and safety of combined adsorbed tetanus, low dose diphtheria, five component acellular pertussis and inactivated poliomyelitis vaccine (Td5aP-IPV), concomitant combined adsorbed tetanus, low dose diphtheria and five component acellular pertussis vaccine (Td5aP) and oral poliomyelitis vaccine (OPV) and combined adsorbed diphtheria, tetanus, two component acellular pertussis and inactivated poliomyelitis vaccine (DT2aP-IPV) given to healthy UK children a minimum of 3 years after priming with diphtheria, tetanus and whole cell pertussis (DTwP) vaccine at 2, 3 & 4 months of age.
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41402
    Study title: Comparative Safety and lmmunogenicity Study of Diphtheria, Tetanus, Acellular Pertussis, Poliomyelitis Vaccine (DTacP-IPV) and Diphtheria, Tetanus, Whole-cell Pertussis, Poliomyelitis 1 1 Vaccine (TETRACOC!@) Given as a Second Booster to 4- to 7-year-old Children
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47159
    Study title: Comparative study of acellular and whole ce11 pertussis vaccines combined with diphtheria, tetanus and inactivated poliomyelitis type 1, 2, 3 vaccines in healthy infants (primary-immunisation and booster).
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47166
    Study title: Comparative study of the safety and immunogeniciîy of a DT Acellular Pertussis and a DT Whole cell Pertussis vaccine in Senegalese infants
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47165
    Study title: Randomised, Open Trial of the lmmunogenicity and Safety of Diphtheria, Tetanus, Acellular Pertussis (DTacP) Vaccine Associated or Combined with PRP-T Vaccine Given at 2-4-6 or 3-4-5 Months in Healthy Infants
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47160
    Study title: Safety and immunogenicity of a combined Diphtheria, Tetanus, acellular Pertussis. Haemophilus influenzae type b, enhanced inactivated trivalent Poliovirus vaccine administered as a single injection to healthy Chilean Infants
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47157
    Study title: STUDY OF SAFETYAND IMMUNOGENICITY AFTER SIMULTANEOUS ADMINISTRATION OF DT~CP-IPV/~/ ct-HIB"V ACCINE AND R.O.R.VAX" (MMR) VACCINE IN 14- TO 16-MONTH-OLD TODDLERS
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47158
    Study title: Trial on the persistence of antibodies 4 years after a first booster with PENTAVAC vaccine and the immunogenicity and safety of a second booster with TETRAVAC-ACELLULAIRE vaccine at the age of 5-6 years.
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 41401
    Study title: DOSE RESPONSE STUDY OF A DIPHTHERIA, TETANUS, ACELLULAR PERTUSSIS (DTacP) VACCINE IN 3-MONTH-OLD CHILDREN
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47155
    Study title: Evaluation of the P.M. SV. Diphtheria, Tetanus, acellular Pertussis vaccine in infants during a NlAlD multicenter acellular Pertussis trial. Comparative study between P.M. SV. DTacP and two conventional whole cell DTP vaccines
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47164
    Study title: Large Scale Safety Study of the DTacP-IPV (Acellular ~etraco~@Va)c cine, Adrninistered in Combination (one injection site) or in Association (two injection sites) with Haemophilus influenzae type b Vaccine (Act-HIE"') for Primary and Booster immunisation.
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47156
    Study title: lmmunogenicity and reactogenicity of two dosages of acellular pettussis vaccine compared with whole-cell pertussis vaccine at prirnary (2, 4 and 6 rnonths of age) and booster (1 5-24 months'and 4-6 years of age) immunisation
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47161
    Study title: Phase III trial on the persistence of antibodies 5 years after a primo-vaccination and 4 years after a first booster with PENTAVAC® vaccine and the immunogenicity and safety of a second booster with TETRAVAC-ACELLULAIRE® vaccine at the age of 5-6 years.
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47162
    Study title: Randomised double-blind study of the relative efficacy and safety of an acellular pertussis vaccine with respect to a whole-cell vaccine among children of rural Senegal (Niakhar)
    Active substance: Adorbed, inactivated diphteria, tetanus, acellular pertussis and poliomyelitis vaccine
    Study summary document link (including results):
    View full study record
    Document reference: 47154
    Study title: Multidetector CT in evaluating blood supply of hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39895
    Study title: Samoilenko I.G.,Yulish E.I., Gadetskaya S.G., Buchtiarov E.V.: New approach to treat pediatric patients suffering from bronchial asthma associated with intracellular infection. Biological Therapy (Ukraine), 2006, 4: 10-13 [IIT-publication]
    Active substance: Echinacea compositum-Heel - Ampullen
    Study summary document link (including results):
    View full study record
    Document reference: 39861
    Study title: Postoperative adjuvant locoregional chemotherapy in patients with hepatocellular carcinoma.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39932
    Study title: Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children.
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39905
    Study title: Preoperative Chemoembolization for Hepatocellular Carcinoma
    Active substance: Ethyl esters of iodized fatty acids of poppy seed oil
    Study summary document link (including results):
    View full study record
    Document reference: 39951
    1  2  3  4  5  6  7  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 10 21:17:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA